Tests a PET imaging agent for finding prostate cancer in newly diagnosed men
Tests a new PET scan imaging agent, 68Ga-NYM032, in men with newly diagnosed prostate cancer.
Plain-language title generated from the registry record
Registry title: Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
Key facts
- Where
- Nanjing and Wuxi, ChinaSee the 2 sites
- Phase
- Phase 3
Where in China
- Affiliated Drum Tower Hospital, Medical School of Nanjing UniversityNanjing, ChinaTaking people
- Affiliated Hospital of Jiangnan UniversityWuxi, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Norroy Bioscience Co., LTD
- Trial code
- NCT07615101
- Record updated
- 17 August 2026
- Original description
The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.Read full original descriptionShow less
Open-label, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.
Inclusion: Patient is male and aged >18 years old; Biopsy proven prostate adenocarcinoma; Patients electing to undergo Radical Prostatectomy (RP) with Pelvic lymph node dissection (PLND); ECOG performance status 0-2; expected survival ≥ 6 months; Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion: 1. Participants who have previously participated in other interventional clinical trials and are within five physical half-lives, or have received radionuclide agents previously with an interval of less than ten physical half-lives prior to study drug injection; Participants administered any IV iodinated contrast medium within 24 hours, or any high density oral contrast medium (oral water contrast is acceptable) within 5 days, prior to study drug injection; Known hypersensitivity to the active ingredient or excipients of the study drug; Participants not capable of getting PET study , or inability to lay still for the duration of the exam; Any medical condition or circumstance that, in the investigator's judgment, may compromise study safety or patient compliance.